News
  Date Title View
Jul 24, 2014
- Sandesh (Sandy) Mahatme of Sarepta Therapeutics Appointed New Board Member ¬†- Flexion CEO Michael Clayman Offers Thanks to Departing Board Member Dr. Rafaéle Tordjman¬† BURLINGTON, Mass., July 24, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today changes to the composition of its Board of Directors. Sandesh...
Jun 17, 2014
- Following intra-articular injection, sustained release of triamcinolone acetonide (TCA) from FX006 maintained therapeutic concentration levels in knee joints of patients through 12 weeks -- Pharmacokinetic (PK) data support previously completed Phase 2b dose-ranging efficacy trial that demonstrated superior magnitude and duration of pain relief o...
Jun 12, 2014
- PathoGenetix President & CEO Ann Merrifield Appointed New Board Member -- Flexion CEO Michael Clayman Offers Thanks to Departing Board Members Bradley Bolzon and Elaine Jones - BURLINGTON, Mass., June 12, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today recent changes to its Board of Directors. Ann Merrifield,...
Jun 11, 2014
BURLINGTON, Mass., June 11, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that CEO Michael Clayman, M.D., will present at the Wells Fargo Securities Research, Economics & Strategy 2014 Healthcare Conference at 3:00 p.m. Eastern Time on Wednesday, June 18, 2014 at the Intercontinental Hotel in Boston. To acces...
May 27, 2014
BURLINGTON, Mass., May 27, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that CEO Michael Clayman, M.D., will present an overview of the company at the 2014 Jefferies Healthcare Conference. Dr. Clayman's presentation is scheduled for June 2, 2014, at 10:30 a.m. Eastern Time. The conference will take place June 2-...
May 8, 2014
Key HighlightsCompleted enrollment of FX006 Phase 2a synovial fluid pharmacokinetics clinical trial with topline data expected in Q2 2014Initiated confirmatory FX006 Phase 2b clinical trial to determine an optimal safe and efficacious dose compared to placebo Added key personnel in Quality Assurance and Regulatory Affairs Significantly bolstered ca...
May 1, 2014
BURLINGTON, Mass., May 1, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to report its first quarter 2014 financial results on Thursday, May 8, 2014, at 4:30 p.m. ET. The dial-in number for the conference call is toll-free (855) 770-0022 for domestic participants...
Apr 30, 2014
BURLINGTON, Mass., April 30, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that the first patient has been dosed in a confirmatory Phase 2b clinical trial designed to further evaluate the safety, tolerability and efficacy of certain doses of FX006 as a treatment for relieving pain associated with OA of the knee. ...
Apr 2, 2014
BURLINGTON, Mass., April 2, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that CEO Michael Clayman, M.D., will present an overview of the company at the 13th Annual Needham Healthcare Conference. Dr. Clayman's presentation is scheduled for April 9, 2014, at 1:40 p.m. Eastern Time. The conference will take place A...
Mar 27, 2014
- Strong cash position bolstered with additional $75 million from IPO -- Lead drug candidate, FX006, planned to enter into confirmatory Phase 2b trial in osteoarthritis of the knee - - Second clinical candidate, FX007, expected to enter Phase 2 proof-of-concept trial later in 2014 - BURLINGTON, Mass., March 27, 2014 (GLOBE NEWSWIRE) -- Flex...
FirstPrevious ...
10
NextLast
= add release to Briefcase